Key result
Lower PON1 enzyme activity in serum and BAL is associated with lung cancer.
Why the study?
Paraoxonase enzyme plays a key role in preventing oxidative stress and removing carcinogenic lipid-soluble radicals, but its diagnostic utility in lung cancer is unclear.
Does paraoxonase (PON1) enzyme activity in serum and bronchoalveolar lavage differ between patients with lung cancer and healthy volunteers?
Case-Control (n=40)
Does paraoxonase (PON1) enzyme activity in serum and bronchoalveolar lavage differ between patients with lung cancer and healthy volunteers?
PON1 enzyme levels in serum and bronchoalveolar lavage are significantly lower in lung cancer patients and may serve as potential biomarkers for the disease.
Answers are grounded in this paper and cite their sources.
Lower PON1 levels may support biomarker exploration in lung cancer; leaves open prospective validation before any diagnostic use.
Backgrounds PON1 plays a main role in preventing oxidative stress, and also it is important in removal of carcinogenic lipid-soluble radicals caused by lipid peroxidation. Bronchoalveolar lavage (BAL) is a sampling technique used in flexible bronchoscopy that can detect several biochemical agents that could be used as possible lung cancer biomarkers. Objectives To investigate the diagnostic utility of serum and BAL levels of paraoxonase enzyme in patients with lung cancer. Patients and methods The study included two groups: group I consisted of 25 patients diagnosed as having lung cancer, and group II consisted of 15 healthy volunteers. Clinical history taking, physical examination, radiological investigations such as chest radiograph and computed tomography, and routine laboratory tests were done for all studied cases. Serum and BAL samples were collected from all studied cases to evaluate PON1 enzyme activity by ELISA test. Results Paraoxonase enzyme was significantly lower in serum and BAL fluid samples in lung cancer cases compared with healthy persons. A significant positive correlation between PON1 levels was found in BAL and serum, and also there were significant positive correlations comparing PON1 enzymatic activity and lipid parameters (high-density lipoprotein, low-density lipoprotein, and cholesterol). Conclusion Levels of PON1 and its related variables could be used as good biomarkers for assessing patients with lung cancer.
No takes yet. Share an insight, caveat, or question.
Elseady et al. (2022) conducted a case-control in Lung cancer (n=40). Lung cancer vs. Healthy volunteers was evaluated on Paraoxonase (PON1) enzyme activity in serum and bronchoalveolar lavage fluid. Paraoxonase (PON1) enzyme activity in serum and bronchoalveolar lavage fluid was significantly lower in patients with lung cancer compared with healthy volunteers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: